[go: up one dir, main page]

MXPA03001495A - Derivados de fenilalanina novedosos. - Google Patents

Derivados de fenilalanina novedosos.

Info

Publication number
MXPA03001495A
MXPA03001495A MXPA03001495A MXPA03001495A MXPA03001495A MX PA03001495 A MXPA03001495 A MX PA03001495A MX PA03001495 A MXPA03001495 A MX PA03001495A MX PA03001495 A MXPA03001495 A MX PA03001495A MX PA03001495 A MXPA03001495 A MX PA03001495A
Authority
MX
Mexico
Prior art keywords
phenylalanine derivatives
new phenylalanine
integrin
chem
alpha
Prior art date
Application number
MXPA03001495A
Other languages
English (en)
Inventor
Takashi Tsuji
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of MXPA03001495A publication Critical patent/MXPA03001495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03001495A 2000-08-18 2001-08-15 Derivados de fenilalanina novedosos. MXPA03001495A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000248728 2000-08-18
JP2001147451 2001-05-17
PCT/JP2001/007039 WO2002016329A1 (en) 2000-08-18 2001-08-15 Novel phenylalanine derivatives

Publications (1)

Publication Number Publication Date
MXPA03001495A true MXPA03001495A (es) 2003-06-06

Family

ID=26598103

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001495A MXPA03001495A (es) 2000-08-18 2001-08-15 Derivados de fenilalanina novedosos.

Country Status (27)

Country Link
US (4) US7153963B2 (es)
EP (1) EP1288205B1 (es)
JP (1) JP3440469B2 (es)
KR (1) KR100675036B1 (es)
CN (1) CN1325480C (es)
AT (1) ATE497385T1 (es)
AU (2) AU2001278740B9 (es)
BG (1) BG66085B1 (es)
BR (1) BRPI0113331B8 (es)
CA (1) CA2420040C (es)
CZ (1) CZ302653B6 (es)
DE (1) DE60143984D1 (es)
DK (1) DK1288205T3 (es)
HU (1) HU228914B1 (es)
IL (2) IL154350A0 (es)
MX (1) MXPA03001495A (es)
NO (1) NO325738B1 (es)
NZ (1) NZ524122A (es)
PL (1) PL223152B1 (es)
PT (1) PT1288205E (es)
RU (1) RU2286340C2 (es)
SI (1) SI1288205T1 (es)
SK (1) SK287781B6 (es)
TW (1) TWI229077B (es)
UA (1) UA74385C2 (es)
WO (1) WO2002016329A1 (es)
YU (1) YU12203A (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
EP1288205B1 (en) * 2000-08-18 2011-02-02 Ajinomoto Co., Inc. Novel phenylalanine derivatives
ATE345127T1 (de) 2000-09-29 2006-12-15 Ajinomoto Kk Neue phenylalanin-derivate
JP4164871B2 (ja) * 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
EP1454898A4 (en) * 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
ATE464299T1 (de) 2002-02-20 2010-04-15 Ajinomoto Kk Neues phenylalaninderivat
WO2004074264A1 (ja) 2003-02-20 2004-09-02 Ajinomoto Co., Inc. キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体
PL1683524T3 (pl) * 2003-11-14 2011-06-30 Ea Pharma Co Ltd Stała dyspersja lub preparat farmaceutyczny stałej dyspersji pochodnej fenyloalaniny
EP1683525B1 (en) * 2003-11-14 2017-05-17 EA Pharma Co., Ltd. Sustained-release phenylalanine derivative preparation for oral administration
ES2451140T3 (es) * 2003-11-27 2014-03-26 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina y método para su producción
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
US20060024295A1 (en) * 2004-06-04 2006-02-02 Genentech, Inc. Method for treating lupus
EP1753455A2 (en) * 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
KR20080046135A (ko) 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
CA2613249A1 (en) * 2005-06-21 2006-12-28 Ajinomoto Co., Inc. Crystals of phenylalanine derivatives, production method thereof and use thereof
EP1957476A1 (en) * 2005-11-23 2008-08-20 AstraZeneca AB L-alanine derivatives
ES2684821T3 (es) 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Derivados de aminoácidos multicíclicos y métodos de su uso
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
TW200808731A (en) * 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
TW200811164A (en) 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
US20080045521A1 (en) * 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
AU2007262147B2 (en) * 2006-06-19 2012-08-16 Toray Industries, Inc. Therapeutic or prophylactic agent for multiple sclerosis
AU2007262083B2 (en) * 2006-06-20 2012-01-19 Toray Industries, Inc. Therapeutic or prophylactic agent for leukemia
RU2469028C2 (ru) 2006-11-22 2012-12-10 Адзиномото Ко., Инк. Способ получения производных фенилаланина с хиназолиндионовым скелетом и промежуточных соединений, применяемых при получении таких производных
US20090062267A1 (en) * 2007-01-29 2009-03-05 Astrazeneca Ab L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011122620A1 (ja) 2010-03-29 2011-10-06 味の素株式会社 フェニルアラニン誘導体を含有する医薬製剤
JP6109568B2 (ja) * 2010-03-29 2017-04-05 Ｅａファーマ株式会社 フェニルアラニン誘導体の塩の結晶
AU2012325013A1 (en) 2011-10-17 2014-03-27 Westfaelische Wilhelms-Universitaet Muenster Methods of risk assessment of PML and related apparatus
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
MX351225B (es) 2012-04-24 2017-10-05 Ea Pharma Co Ltd Derivado de sulfonamida y uso medicinal del mismo.
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
CN109867630A (zh) * 2013-06-11 2019-06-11 赛尔基因第二国际有限公司 新型glp-1受体调节剂
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EP3064491B1 (en) 2013-10-29 2020-01-08 EA Pharma Co., Ltd. Sulfonamide derivative and medicinal use thereof
KR102319078B1 (ko) * 2014-09-29 2021-10-29 이에이 파마 가부시키가이샤 궤양성 대장염의 치료용 의약 조성물
US10307535B2 (en) 2014-12-19 2019-06-04 Medtronic Minimed, Inc. Infusion devices and related methods and systems for preemptive alerting
JP2018515424A (ja) 2015-03-10 2018-06-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗アルファｖベータ１インテグリン阻害剤及び使用方法
LT3359572T (lt) 2015-10-06 2025-02-10 F. Hoffmann-La Roche Ag Išsėtinės sklerozės gydymo būdas
EA036432B1 (ru) 2016-02-05 2020-11-10 Эа Фарма Ко., Лтд. Производные сульфонамида и содержащие их фармацевтические композиции
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US11963996B2 (en) * 2018-10-24 2024-04-23 Orthotrophix, Inc. Method of treating knee pain
IL282545B2 (en) 2018-10-30 2025-04-01 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
EP3905942A4 (en) 2018-12-04 2022-08-31 OrthoTrophix, Inc. FORMULATION FOR TREATMENT OF OSTEOARTHRITIS
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
US11793857B2 (en) 2020-10-01 2023-10-24 Orthotrophix, Inc. Hard tissue therapeutics
WO2025058075A1 (ja) * 2023-09-13 2025-03-20 国立大学法人大阪大学 放射性陽電子放出核種炭素１１標識化合物、及び放射性組成物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2419928A1 (fr) * 1978-03-15 1979-10-12 Metabio Joullie Sa Nouveaux derives de la n-phenylalanine, leur preparation et leur application comme medicaments
DE4111394A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
HU914U (en) 1995-04-19 1996-10-28 Koevesi Machine tool for contour turning
TR199902093T2 (xx) 1997-02-28 1999-12-21 Prizer Products Inc. 3-Aril-4(3H)- kinazolinonlar�n atropizomerleri, bile�iklerinin amparesept�r� antagonistleri olarak kullan�m�.
HUP0003921A3 (en) * 1997-07-31 2001-03-28 Wyeth Corp Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use
CA2290747A1 (en) 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
DE69824183T2 (de) * 1997-08-22 2005-04-21 Hoffmann La Roche N-alkanoylphenylalaninderivate
BR9811988A (pt) 1997-08-22 2000-09-05 Hoffmann La Roche Derivados de n-alcanoilfenilalanina
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
ATE273273T1 (de) 1998-02-26 2004-08-15 Celltech Therapeutics Ltd Phenylalaninderivate als inhibitoren von alpha4 integrinen
GB2354440A (en) 1999-07-20 2001-03-28 Merck & Co Inc Aryl amides as cell adhesion inhibitors
WO2001036376A1 (en) * 1999-11-18 2001-05-25 Ajinomoto Co., Inc. Novel phenylalanine derivatives
WO2001042225A2 (en) 1999-12-06 2001-06-14 F. Hoffmann-La Roche Ag 4-pyrimidinyl-n-acyl-l-phenylalanines
DE60020883T2 (de) 1999-12-06 2006-03-23 F. Hoffmann-La Roche Ag 4-pyridinyl-n-acyl-l-phenylalanine
JP4784803B2 (ja) * 1999-12-28 2011-10-05 味の素株式会社 新規フェニルアラニン誘導体
EP1270547A4 (en) * 2000-03-23 2005-07-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
EP1288205B1 (en) 2000-08-18 2011-02-02 Ajinomoto Co., Inc. Novel phenylalanine derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
ATE345127T1 (de) * 2000-09-29 2006-12-15 Ajinomoto Kk Neue phenylalanin-derivate
JP4164871B2 (ja) * 2001-07-26 2008-10-15 味の素株式会社 新規フェニルプロピオン酸誘導体
EP1454898A4 (en) * 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
ATE464299T1 (de) * 2002-02-20 2010-04-15 Ajinomoto Kk Neues phenylalaninderivat
WO2004074264A1 (ja) * 2003-02-20 2004-09-02 Ajinomoto Co., Inc. キナゾリンジオン骨格を有するフェニルアラニン誘導体の製造方法及び製造中間体
ES2451140T3 (es) * 2003-11-27 2014-03-26 Ajinomoto Co., Inc. Cristal de derivado de fenilalanina y método para su producción
RU2390520C2 (ru) 2003-12-22 2010-05-27 Адзиномото Ко., Инк. Новые производные фенилаланина
CA2613249A1 (en) 2005-06-21 2006-12-28 Ajinomoto Co., Inc. Crystals of phenylalanine derivatives, production method thereof and use thereof

Also Published As

Publication number Publication date
NZ524122A (en) 2005-02-25
US20060223836A1 (en) 2006-10-05
NO20030744L (no) 2003-04-07
EP1288205A1 (en) 2003-03-05
IL154350A (en) 2010-02-17
EP1288205A4 (en) 2007-05-23
DE60143984D1 (de) 2011-03-17
US7872125B2 (en) 2011-01-18
US8222405B2 (en) 2012-07-17
NO20030744D0 (no) 2003-02-17
ATE497385T1 (de) 2011-02-15
HU228914B1 (hu) 2013-06-28
AU2001278740B2 (en) 2006-04-06
CN1469867A (zh) 2004-01-21
US20110065918A1 (en) 2011-03-17
BG107555A (bg) 2003-09-30
WO2002016329A1 (en) 2002-02-28
KR20030048011A (ko) 2003-06-18
BR0113331A (pt) 2004-02-25
AU7874001A (en) 2002-03-04
SK287781B6 (sk) 2011-09-05
RU2286340C2 (ru) 2006-10-27
CN1325480C (zh) 2007-07-11
HUP0302997A3 (en) 2004-03-29
NO325738B1 (no) 2008-07-14
AU2001278740B9 (en) 2006-09-28
CA2420040C (en) 2009-02-03
PL223152B1 (pl) 2016-10-31
HUP0302997A2 (hu) 2004-01-28
BRPI0113331B8 (pt) 2021-05-25
CA2420040A1 (en) 2003-02-18
IL154350A0 (en) 2003-09-17
US8426588B2 (en) 2013-04-23
UA74385C2 (uk) 2005-12-15
US7153963B2 (en) 2006-12-26
SI1288205T1 (sl) 2011-05-31
EP1288205B1 (en) 2011-02-02
TWI229077B (en) 2005-03-11
US20030220268A1 (en) 2003-11-27
CZ2003481A3 (cs) 2003-06-18
CZ302653B6 (cs) 2011-08-17
YU12203A (sh) 2006-03-03
KR100675036B1 (ko) 2007-01-29
US20120253041A1 (en) 2012-10-04
PT1288205E (pt) 2011-05-06
DK1288205T3 (da) 2011-05-23
SK1912003A3 (en) 2003-07-01
BG66085B1 (bg) 2011-03-31
JP3440469B2 (ja) 2003-08-25
BR0113331B1 (pt) 2017-11-14
PL361383A1 (en) 2004-10-04

Similar Documents

Publication Publication Date Title
MXPA03001495A (es) Derivados de fenilalanina novedosos.
ATE355269T1 (de) Phenylalaninderivate
ATE464299T1 (de) Neues phenylalaninderivat
FR20C1039I2 (fr) Derives de l'uk-2a
EP2615087A3 (en) Phenylalanine derivatives
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
ECSP066311A (es) Derivados de la piperazina y su uso como agentes terapéuticos
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
DE60121461D1 (de) Kondensierte pyridoindolderivate
EP1272176A4 (en) ADAMANTYL DERIVATIVES AS AN ANTI-DRINK AGENT
EP1210933A4 (en) ACTIVE SUBSTANCES FOR NORMALIZING THE SKIN CONDITION
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
NO20054662D0 (no) Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
DE69828522D1 (de) Antithrombotische mittel
SE9902742D0 (sv) New pharmaceutical formultion
EP1501350A4 (en) ACTIVATION OF HORSE OOCYTES
DE50310743D1 (de) Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat
ITRM20000624A0 (it) Uso di derivati dell'acidocinnamico come agenti insetticidi.
ECSP972236A (es) Derivados de 6,6- heterobiciclicos sustituidos
ITMI20001398A0 (it) Composizioni farmaceutiche ad elevata attivita' antiossidante verso iradicali liberi

Legal Events

Date Code Title Description
FG Grant or registration